JusticeItaly Official institution

Italy withdraws approval for Celecoxib Maxmind capsules at manufacturer's request

Italy's medicines agency AIFA has withdrawn the marketing permission for Celecoxib Maxmind, a capsule medicine, after its holder Maxmind Pharmaceutical GmbH asked for it to be cancelled. The decision is dated 28 October 2026 and covers ten pack versions in 100 mg and 200 mg strengths. Any leftover stock already in shops and pharmacies may still be sold for up to 180 days after publication.

This summary was generated by AI; the official source prevails.

What does it mean?

Celecoxib Maxmind is a capsule medicine that can no longer be legally sold in Italy, because its maker asked for the approval to be cancelled. Pharmacies may still sell what they already have on hand for up to 180 days after publication. If you take this medicine, talk to your doctor or pharmacist about alternatives.

Who is affected?

Patients who use Celecoxib Maxmind capsules in Italy, and pharmacies and distributors holding stock of it.

What changes?

Celecoxib Maxmind capsules were previously authorized for sale in Italy; now that authorization has been revoked.